Research output

Research output per year 1993 2010 2022 2023 2024

• 156 Article
• 17 Letter
• 8 Review article
• 1 Chapter
• 1 More
  • 1 Comment/debate

Research output per year

Research output per year

Search results

• 2024

  An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States

  Oluwole, O. O., Patel, A. R., Vadgama, S., Smith, N. J., Blissett, R., Feng, C., Dickinson, M., Johnston, P. B. & Perales, M. A., 2024, In: Journal of Medical Economics. 27, 1, p. 77-83 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • axicabtagene ciloleucel 100%
  • B-Cell Lymphoma 53%
  • life years 41%
  • costs 28%
  • Survival 28%

• Day 100 Natural Killer Cell/CD14+HLA-DR^DIM ratio and survival in lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation

  Porrata, L. F., Ansell, S. M., Micallef, I., Johnston, P. B., Villasboas Bisneto, J., Paludo, J., Durani, U. & Markovic, S. N., Jan 2024, In: Clinical Transplantation. 38, 1, e15211.

  Research output: Contribution to journal › Article › peer-review

  • Peripheral Blood Stem Cell Transplantation 100%
  • Hematopoietic Stem Cell Transplantation 80%
  • Natural Killer Cells 69%
  • Lymphoma 62%
  • Progression-Free Survival 48%

• Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy

  Burlile, J. F., Frechette, K. M., Breen, W. G., Hwang, S. R., Higgins, A. S., Nedved, A. N., Harmsen, W. S., Pulsipher, S. D., Witzig, T. E., Micallef, I. N., Hoppe, B. S., Habermann, T. M., Thanarajasingam, G., Johnston, P. B., Inwards, D. J., Bennani, N. N., Peterson, J. L., Stish, B. J., Rule, W., Ansell, S. M., & 1 othersLester, S. C., Mar 12 2024, In: Blood Advances. 8, 5, p. 1250-1267 18 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Pralatrexate injection combined with CHOP for treatment of PTCL: results from the Fol-CHOP dose-finding phase 1 trial

  Iyer, S. P., Johnston, P. B. & Barta, S. K., Jan 23 2024, In: Blood Advances. 8, 2, p. 353-364 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • 10-propargyl-10-deazaaminopterin 100%
  • Peripheral T-Cell Lymphoma 73%
  • Injections 30%
  • VAP-cyclo protocol 27%
  • Maximum Tolerated Dose 21%

• Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience

  Chohan, K. L., Bansal, R., Hathcock, M. A., Paludo, J., Bennani, N. N., Johnston, P. B., Khurana, A., Durani, U., Wang, Y., Ruff, M. W., Villasboas Bisneto, J. C., Ansell, S. M., Lin, Y. & Kenderian, S. S., 2024, In: Leukemia and Lymphoma. 65, 3, p. 389-393 5 p.

  Research output: Contribution to journal › Letter › peer-review

• Serial Evaluation of Preimmunization Antibody Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy

  Bansal, R., Vergidis, P., Tosh, P. K., Wilson, J., Hathcock, M., Khurana, A., Bennani, N. N., Paludo, J., Villasboas Bisneto, J., Wang, Y., Ansell, S. M., Johnston, P. B., Freeman, C. & Lin, Y., 2024, (Accepted/In press) In: Transplantation and Cellular Therapy.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chimeric Antigen Receptors 100%
  • Cell- and Tissue-Based Therapy 70%
  • Lymphoma 61%
  • T-Lymphocytes 45%
  • Antibodies 41%
• 2023

  Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy

  Bezerra, E. D., Iqbal, M., Munoz, J., Khurana, A., Wang, Y., Maurer, M. J., Bansal, R., Hathcock, M. A., Bennani, N., Murthy, H. S., Rosenthal, A. C., Paludo, J., Villasboas, J. C., Johnston, P. B., Habermann, T. M., Ansell, S. M., Castro, J. E., Witzig, T. E., Kharfan-Dabaja, M. A., Nowakowski, G. S., & 1 othersLin, Y., Apr 25 2023, In: Blood Advances. 7, 8, p. 1572-1576 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial

  Herrera, A. F., Chen, L., Nieto, Y., Holmberg, L., Johnston, P., Mei, M., Popplewell, L., Armenian, S., Cao, T., Farol, L., Sahebi, F., Spielberger, R., Chen, R., Nademanee, A., Puverel, S., Nwangwu, M., Lee, P., Song, J., Skarbnik, A., Kennedy, N., & 5 othersPeters, L., Rosen, S. T., Kwak, L. W., Forman, S. J. & Feldman, T., Jan 2023, In: The Lancet Haematology. 10, 1, p. e14-e23

  Research output: Contribution to journal › Article › peer-review

  • Brentuximab Vedotin 100%
  • Nivolumab 85%
  • Hematopoietic Stem Cell Transplantation 66%
  • Hodgkin Disease 64%
  • Progression-Free Survival 13%

• CAR-T Therapy in Lymphoma Patients With Coexisting Cardiomyopathy or Cardiac Lymphomatous Involvement

  Ng, C. T., Gonzalez Bonilla, H. M., Chang, I., Aung, M. T., Gile, J. J., Pereira, N. L., Villasboas Bisneto, J. C., Johnston, P. B., Villarraga, H. R., Rodriguez-Porcel, M. G., Lin, G., Lin, Y. & Herrmann, J., Jun 7 2023, In: JACC: Case Reports. 15, 101840.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chimeric Antigen Receptors 100%
  • Cardiomyopathies 72%
  • Cell- and Tissue-Based Therapy 70%
  • Lymphoma 61%
  • Cardiac Tamponade 46%

• Central nervous system involvement (Bing-Neel Syndrome) in patients with Waldenström macroglobulinemia

  Zanwar, S., Abeykoon, J. P., Ansell, S. M., Gertz, M. A., Mauermann, M., Witzig, T. E., Johnston, P., Kyle, R. A., King, R. L., Habermann, T. M., Kumar, S. & Kapoor, P., 2023, In: Leukemia and Lymphoma. 64, 8, p. 1490-1493 4 p.

  Research output: Contribution to journal › Letter › peer-review

• Central nervous system involvement by mantle cell lymphoma

  McLaughlin, N., Wang, Y., Witzig, T., Villasboas, J., Habermann, T., Inwards, D., Bennani, N., Thanarajasingam, G., Nowakowski, G., Porrata, L., Thompson, C., Micallef, I., Johnston, P., Ansell, S. & Paludo, J., 2023, In: Leukemia and Lymphoma. 64, 2, p. 371-377 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Mantle-Cell Lymphoma 100%
  • Central Nervous System 56%
  • Control Groups 4%
  • Therapeutics 1%

• Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma

  Saifi, O., Breen, W. G., Lester, S. C., Rule, W. G., Stish, B. J., Rosenthal, A., Munoz, J., Lin, Y., Bansal, R., Hathcock, M. A., Johnston, P. B., Ansell, S. M., Paludo, J., Khurana, A., Villasboas, J. C., Wang, Y., Iqbal, M., Moustafa, M. A., Murthy, H. S., Kharfan-Dabaja, M. A., & 2 othersPeterson, J. L. & Hoppe, B. S., Nov 2023, In: Haematologica. 108, 11, p. 2982-2992 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Adoptive Immunotherapy 100%
  • Non-Hodgkin's Lymphoma 71%
  • Radiotherapy 52%
  • Progression-Free Survival 30%
  • Recurrence 28%

• Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma

  Saifi, O., Breen, W. G., Lester, S. C., Rule, W. G., Stish, B. J., Rosenthal, A., Munoz, J., Lin, Y., Bansal, R., Hathcock, M. A., Bennani, N. N., Paludo, J., Khurana, A., Villasboas, J. C., Johnston, P. B., Ansell, S. M., Iqbal, M., Moustafa, M. A., Murthy, H. S., Kharfan-Dabaja, M. A., & 2 othersHoppe, B. S. & Peterson, J. L., Aug 1 2023, In: International Journal of Radiation Oncology Biology Physics. 116, 5, p. 999-1007 9 p.

  Research output: Contribution to journal › Article › peer-review

  • horses 100%
  • Chimeric Antigen Receptors 95%
  • Adoptive Immunotherapy 92%
  • antigens 89%
  • B-Cell Lymphoma 73%

• End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET

  Chohan, K. L., Young, J. R., Lester, S., Moustafa, M. A., Rosenthal, A., Tun, H. W., Hoppe, B. S., Johnston, P. B., Micallef, I. N., Habermann, T. M. & Ansell, S. M., Jun 2023, In: Haematologica. 108, 6, p. 1697-1701 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

  TRANSFORM Investigators, Apr 6 2023, In: Blood. 141, 14, p. 1675-1684 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Refractory 100%
  • B-Cell Lymphoma 99%
  • Standard of Care 93%
  • Progression-Free Survival 43%
  • antigen 106 19%

• Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity

  Breen, W. G., Young, J. R., Hathcock, M. A., Kowalchuk, R. O., Thorpe, M. P., Bansal, R., Khurana, A., Bennani, N. N., Paludo, J., Bisneto, J. V., Wang, Y., Ansell, S. M., Peterson, J. L., Johnston, P. B., Lester, S. C. & Lin, Y., Dec 2023, In: Blood cancer journal. 13, 1, 127.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • axicabtagene ciloleucel 100%
  • Chimeric Antigen Receptors 69%
  • Non-Hodgkin's Lymphoma 48%
  • Tumor Burden 40%
  • Leukapheresis 35%

• Outcomes of Older Adults with Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation: A Mayo Clinic Cohort Analysis

  Wudhikarn, K., Johnson, B. M., Inwards, D. J., Porrata, L. F., Micallef, I. N., Ansell, S. M., Hogan, W. J., Paludo, J., Villasboas, J. C. & Johnston, P. B., Mar 2023, In: Transplantation and Cellular Therapy. 29, 3, p. 176.e1-176.e8

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Stem Cell Transplantation 100%
  • Non-Hodgkin's Lymphoma 90%
  • Cohort Studies 65%
  • Lymphoma 33%
  • Cell Transplantation 17%

• Outcomes of Patients with Classic Hodgkin Lymphoma Who Relapsed after Autologous Stem Cell Transplant

  Tun, A. M., Wang, Y., Matin, A., Inwards, D. J., Habermann, T. M., Micallef, I., Johnston, P. B., Porrata, L., Paludo, J., Bisneto, J. V., Rosenthal, A., Tun, H. W., Cerhan, J. R., Witzig, T. E., Nowakowski, G. S. & Ansell, S. M., Apr 4 2023, In: HemaSphere. 7, 4, p. E869

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hodgkin Disease 100%
  • Stem Cells 71%
  • Transplants 60%
  • Brentuximab Vedotin 58%
  • Progression-Free Survival 55%

• Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma

  Acosta-Medina, A. A., Johnson, I. M. K., Bansal, R., Hathcock, M., Kenderian, S. J., Durani, U., Khurana, A., Wang, Y., Paludo, J., Villasboas, J. C., Bennani, N. N., Johnston, P. B., Ansell, S. M., Lin, Y. & Alkhateeb, H. B., Dec 2023, In: Blood cancer journal. 13, 1, 7.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T-cell therapy recipients

  Powell, M. Z., Mara, K. C., Bansal, R., Hathcock, M. A., Khurana, A., Bennani, N. N., Wang, Y., Paludo, J., Bisneto, J. V., Ansell, S. M., Johnston, P. B., Lin, Y. & Barreto, J. N., Apr 2023, In: Cancer medicine. 12, 8, p. 9228-9235 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chimeric Antigen Receptors 100%
  • Procalcitonin 94%
  • Cell- and Tissue-Based Therapy 70%
  • Bacterial Infections 69%
  • Biomarkers 48%

• Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma

  Wiedmeier-Nutor, J. E., Iqbal, M., Rosenthal, A. C., Bezerra, E. D., Garcia-Robledo, J. E., Bansal, R., Johnston, P. B., Hathcock, M., Larsen, J. T., Bergsagel, P. L., Wang, Y., Reeder, C. B., Leis, J. F., Fonseca, R., Palmer, J. M., Gysbers, B. J., Mwangi, R., Warsame, R. M., Kourelis, T., Hayman, S. R., & 15 othersDingli, D., Kapoor, P., Kumar, S. K., Durani, U., Villasboas, J. C., Paludo, J., Bennani, N. N., Nowakowski, G., Ansell, S. M., Castro, J. E., Kharfan-Dabaja, M. A., Lin, Y., Vergidis, P., Murthy, H. S. & Munoz, J., Jun 2023, In: Clinical Lymphoma, Myeloma and Leukemia. 23, 6, p. 456-462 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chimeric Antigen Receptors 100%
  • Multiple Myeloma 73%
  • Cell- and Tissue-Based Therapy 70%
  • Non-Hodgkin's Lymphoma 69%
  • Vaccination 59%

• Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma

  Westin, J. R., Locke, F. L., Dickinson, M., Ghobadi, A., Elsawy, M., van Meerten, T., Miklos, D. B., Ulrickson, M. L., Perales, M. A., Farooq, U., Wannesson, L., Leslie, L., Kersten, M. J., Jacobson, C. A., Pagel, J. M., Wulf, G., Johnston, P., Rapoport, A. P., Du, L., Vardhanabhuti, S., & 7 othersFilosto, S., Shah, J., Snider, J. T., Cheng, P., To, C., Oluwole, O. O. & Sureda, A., May 15 2023, In: Clinical Cancer Research. 29, 10, p. 1894-1905 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • axicabtagene ciloleucel 100%
  • B-Cell Lymphoma 53%
  • Standard of Care 49%
  • Safety 29%
  • Patient Reported Outcome Measures 21%
• 2022

  Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS)

  Saw, J. L., Sidiqi, M. H., Ruff, M., Hocker, S., Alkhateeb, H., Ansell, S. M., Bennani, N. N., Dingli, D., Hayman, S. R., Johnston, P. B., Kapoor, P., Kenderian, S. J., Kourelis, T. V., Kumar, S. K., Paludo, J., Shah, M. V., Siddiqui, M. A., Warsame, R., Rosenthal, A., Grill, M., & 6 othersCastro, J. E., Siegel, J., Abdel Rahman, Z. H., Kharfan-Dabaja, M. A., So, E. & Lin, Y., Apr 2022, In: Blood cancer journal. 12, 4, 62.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome

  Chohan, K. L., Young, J. R., Lester, S., Moustafa, M. A., Rosenthal, A., Tun, H. W., Hoppe, B. S., Johnston, P. B., Micallef, I. N., Habermann, T. M. & Ansell, S. M., Jul 26 2022, In: Blood Advances. 6, 14, p. 4241-4250 10 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Combined Modality Therapy 100%
  • Hodgkin Disease 82%
  • Drug Therapy 47%
  • Progression-Free Survival 27%
  • Clinical Trials 13%

• Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003–2018)

  Seegobin, K., Li, Z., Alhaj Moustafa, M., Majeed, U., Wang, J., Jiang, L., Kuhlman, J., Menke, D., Li, K., Kharfan-Dabaja, M. A., Ayala, E., Iqbal, M., Nowakowski, G. S., Habermann, T. M., Witzig, T. E., Johnston, P., Thompson, C., Ansell, S. & Tun, H. W., Sep 2022, In: American journal of hematology. 97, 9, p. 1150-1158 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lymphoma 100%
  • Survival 66%
  • Skin 36%
  • Rituximab 28%
  • Biopsy 16%

• CT-009 Prognostic Role of Lymphocyte to Monocyte Ratio in PTS Treated With CAR-T for Aggressive Lymphoma

  Bansal, R., Zhang, H., Martinez, K. E., Hathcock, M., Shao, Z., McCoy, G. G., Gonzalez-Guerrico, A., Bennani, N., Paludo, J., Wang, Y., Johnston, P. B., Ansell, S. M., Kenderian, S., Porrata, L., Villasboas, J. C. & Lin, Y., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S430

  Research output: Contribution to journal › Article › peer-review

  • Lymphoma 100%
  • Monocytes 99%
  • Lymphocytes 83%
  • Phenotype 72%
  • axicabtagene ciloleucel 58%

• CT-016 Prognostic Role of Lymphocyte-to-Monocyte Ratio in Patients Treated With CAR-T for Aggressive Lymphoma

  Bansal, R., Zhang, H., Martinez, K., Hathcock, M., Shao, Z., McCoy, G., Guerrico, A. G., Bennani, N., Paludo, J., Wang, Y., Johnston, P., Ansell, S., Kenderian, S., Porrata, L., Bisneto, J. V. & Lin, Y., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S430

  Research output: Contribution to journal › Article › peer-review

  • Chimeric Antigen Receptors 100%
  • T-Cell Lymphoma 85%
  • Monocytes 61%
  • Lymphocytes 51%
  • T-Lymphocytes 45%

• Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?

  Saifi, O., Breen, W. G., Lester, S. C., Rule, W. G., Stish, B., Rosenthal, A., Munoz, J., Herchko, S. M., Murthy, H. S., Lin, Y., Bansal, R., Hathcock, M. A., Bennani, N. N., Paludo, J., Wang, Y., Khurana, A., Bisneto, J. C. V., Johnston, P. B., Ansell, S. M., Iqbal, M., & 5 othersTun, H., Ayala, E., Kharfan-Dabaja, M. A., Hoppe, B. S. & Peterson, J. L., Jan 2022, In: Radiotherapy and Oncology. 166, p. 171-179 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Adoptive Immunotherapy 100%
  • Non-Hodgkin's Lymphoma 71%
  • Radiotherapy 52%
  • Chimeric Antigen Receptors 46%
  • Cell- and Tissue-Based Therapy 32%

• Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL

  Abramson, J. S., Johnston, P. B., Kamdar, M., Ibrahimi, S., Izutsu, K., Arnason, J., Glass, B., Mutsaers, P., Lunning, M., Braverman, J., Liu, F. F., Crotta, A., Montheard, S., Previtali, A., Guo, S., Shi, L. & Solomon, S. R., Dec 13 2022, In: Blood Advances. 6, 23, p. 5969-5979 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • B-Cell Lymphoma 100%
  • Standard of Care 93%
  • Quality of Life 62%
  • Global Health 40%
  • Health Status 35%

• High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course

  O'Donoghue, D. F., Truong, H. L., Finnes, H. D., McDonald, J. S., May, H. P., Ansell, S. M., Bennani, N. N., Habermann, T. M., Inwards, D. J., Johnston, P. B., Khurana, A., Lin, Y., Micallef, I. N., Nowakowski, G. S., Paludo, J., Porrata, L. F., Thanarajasingam, G., Thompson, C. A., Villasboas, J. C., Wang, Y., & 2 othersWitzig, T. E. & Leung, N., Dec 1 2022, In: JCO Oncology Practice. 18, 12, p. E1908-E1917

  Research output: Contribution to journal › Article › peer-review

  • Methotrexate 100%
  • Acute Kidney Injury 98%
  • incidence 87%
  • Lymphoma 85%
  • Length of Stay 62%

• Hodgkin Lymphoma, Version 2.2022 Featured Updates to the NCCN Guidelines

  Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Armand, P., Bello, C. M., Benitez, C. M., Chen, W., Dabaja, B., Daly, M. E., Gordon, L. I., Hansen, N., Herrera, A. F., Hochberg, E. P., Johnston, P. B., Kaminski, M. S., Kelsey, C. R., Kenkre, V. P., Khan, N., Lynch, R. C., & 17 othersMaddocks, K., McConathy, J., Metzger, M., Morgan, D., Mulroney, C., Pullarkat, S. T., Rabinovitch, R., Rosenspire, K. C., Seropian, S., Tao, R., Torka, P., Winter, J. N., Yahalom, J., Yang, J. C., Burns, J. L., Campbell, M. & Sundar, H., Apr 2022, In: JNCCN Journal of the National Comprehensive Cancer Network. 20, 4, p. 322-334 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hodgkin Disease 100%
  • Guidelines 62%
  • B-Lymphocytes 10%
  • Radiotherapy 9%
  • Therapeutics 4%

• IBCL-333 Follicular Lymphoma (FL) 3B Patients Have a Superior Risk of an Aggressive Disease at First Event Compared to Those With FL1–3A Treated With Front-Line R-CHOP

  Mondello, P., Smith, A., Link, B., Feldman, A., Habermann, T., Wang, Y., Micallef, I., Johnston, P., Nowakowski, G., Cerhan, J., Maurer, M. & Ansell, S., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S389

  Research output: Contribution to journal › Article › peer-review

  • Follicular Lymphoma 100%
  • Progression-Free Survival 28%
  • Lymphoma, Large B-Cell, Diffuse 21%
  • Retreatment 7%
  • Molecular Epidemiology 7%

• Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation

  Porrata, L. F., Inwards, D. J., Ansell, S. M., Micallef, I. N., Johnston, P. B., Villasboas, J. C., Paludo, J. & Markovic, S. N., 2022, In: Leukemia and Lymphoma. 63, 10, p. 2436-2443 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Autografts 100%
  • Lymphocyte Count 99%
  • Stem Cell Transplantation 96%
  • Lymphoma 76%
  • Peripheral Blood Stem Cell Transplantation 69%

• Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma

  Iqbal, M., Castano, Y. G., Paludo, J., Rosenthal, A., Li, Z., Beltran, M., Moustafa, M. A., Inwards, D., Porrata, L., Micallef, I., Bisneto, J. C. V., Johnston, P., Ansell, S. M., Reeder, C., Murthy, H., Roy, V., Foran, J., Tun, H. W., Kharfan-Dabaja, M. A. & Ayala, E., Feb 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, 2, p. e89-e95

  Research output: Contribution to journal › Article › peer-review

  • Lymphoma, Large B-Cell, Diffuse 100%
  • B-Lymphocytes 68%
  • Germinal Center 58%
  • Transplants 55%
  • Fluorescence In Situ Hybridization 9%

• Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey

  Harkins, R. A., Patel, S. P., Lee, M. J., Switchenko, J. M., Ansell, S. M., Bartlett, N. L., Blum, K. A., Cashen, A. F., Casulo, C., Friedberg, J. W., Johnston, P. B., Kahl, B. S., Leonard, J. P., Link, B. K., Lossos, I. S., Martin, P., Maurer, M. J., Mehta-Shah, N., Reagan, P. M., Westin, J. R., & 2 othersKoff, J. L. & Flowers, C. R., May 10 2022, In: Blood Advances. 6, 9, p. 2745-2756 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lymphoma, Large B-Cell, Diffuse 100%
  • Randomized Controlled Trials 59%
  • Lymphoma 18%
  • Rituximab 12%
  • Vincristine 12%

• Incidence and Risk Factors for Acute Kidney Injury After Chimeric Antigen Receptor T-Cell Therapy

  Farooqui, N., Sy-Go, J. P. T., Miao, J., Mehta, R., Vaughan, L. E., Bennani, N. N., Wang, Y., Bansal, R., Hathcock, M. A., Hayman, S. R., Johnston, P. B., Villasboas, J. C., Paludo, J., Ansell, S. M., Leung, N., Lin, Y. & Herrmann, S. M., Jul 2022, In: Mayo Clinic proceedings. 97, 7, p. 1294-1304 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chimeric Antigen Receptors 100%
  • Acute Kidney Injury 70%
  • Cell- and Tissue-Based Therapy 70%
  • T-Lymphocytes 45%
  • Incidence 36%

• Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience

  Melody, M., Gandhi, S., Saunders, H., Abdel-Rahman, Z., Hastings, J., Lengerke Diaz, P., Gannon, N., Truong, T., Hathcock, M., Khurana, A., Johnston, P., Ansell, S., Bennani, N., Paludo, J., Bisneto, J. V., Wang, Y., Rosenthal, A., Foran, J., Ayala, E., Murthy, H. S., & 4 othersRoy, V., Castro, J. E., Lin, Y. & Kharfan-Dabaja, M. A., 2022, In: Leukemia and Lymphoma. 63, 6, p. 1363-1368 6 p.

  Research output: Contribution to journal › Article › peer-review

  • axicabtagene ciloleucel 100%
  • B-Cell Lymphoma 53%
  • Thrombosis 39%
  • Cytokine Release Syndrome 33%
  • Chimeric Antigen Receptors 27%

• Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience

  Kuhlman, J. J., Moustafa, M. A., Jiang, L., Iqbal, M., Seegobin, K., Wolcott, Z., Ayala, E., Ansell, S., Rosenthal, A., Paludo, J., Micallef, I., Johnston, P., Inwards, D., Habermann, T., Kharfan-Dabaja, M., Witzig, T. E., Nowakowski, G. S. & Tun, H. W., Aug 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, 8, p. e815-e825

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Central Nervous System Diseases 100%
  • B-Cell Lymphoma 94%
  • Non-Hodgkin's Lymphoma 86%
  • Lymphoma 37%
  • B-Lymphocytes 17%

• Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

  TRANSFORM Investigators, Jun 18 2022, In: The Lancet. 399, 10343, p. 2294-2308 15 p.

  Research output: Contribution to journal › Article › peer-review

  • Stem Cell Transplantation 100%
  • B-Cell Lymphoma 98%
  • Standard of Care 92%
  • Drug Therapy 56%
  • Chimeric Antigen Receptors 38%

• Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis

  Strouse, C. S., Larson, M. C., Ehlers, S. L., Yost, K. J., Maurer, M. J., Ansell, S. M., Inwards, D. J., Johnston, P. B., Micallef, I. N., Link, B. K., Farooq, U., Cerhan, J. R. & Thompson, C. A., May 1 2022, In: JCO Oncology Practice. 359, 2100694.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • cohort analysis 100%
  • Cell Transplantation 76%
  • Lymphoma 58%
  • quality of life 56%
  • Cohort Studies 48%

• Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT

  Breen, W. G., Hathcock, M. A., Young, J. R., Kowalchuk, R. O., Bansal, R., Khurana, A., Bennani, N. N., Paludo, J., Villasboas Bisneto, J. C., Wang, Y., Ansell, S. M., Peterson, J. L., Johnston, P. B., Lester, S. C. & Lin, Y., Dec 2022, In: Journal of Hematology and Oncology. 15, 1, 36.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

  • Chimeric Antigen Receptors 100%
  • Lymphoma 61%
  • T-Lymphocytes 45%
  • Glycolysis 21%
  • Tumor Burden 19%

• Peak absolute lymphocyte count after CAR-T infusion predicts clinical response in aggressive lymphoma

  Bansal, R., Novo, M., Al Saleh, A. S., Guerrico, A. G., Zhang, H., Shao, Z., Babadi, E., Martinez, K. E., McCoy, G. A., Hathcock, M. A., Khurana, A., Bennani, N. N., Paludo, J., Wang, Y., Ansell, S. M., Johnston, P. B., Villasboas, J. C. & Lin, Y., Jul 2022, In: American journal of hematology. 97, 7, p. E241-E244

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Pemetrexed Plus Lenalidomide for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Prospective Single-Arm Phase II Study

  Ma, J., Lin, Z., Ding, T., Li, Q., Zhang, M., Kang, H., Johnston, P. B., Ma, Y. & Chen, B., Jul 11 2022, In: Frontiers in Oncology. 12, 938421.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lenalidomide 100%
  • Pemetrexed 98%
  • Lymphoma 62%
  • Central Nervous System 55%
  • Progression-Free Survival 34%

• Perineural spread of peripheral neurolymphomatosis to the cauda equina

  Murthy, N. K., Amrami, K. K., Broski, S. M., Johnston, P. B. & Spinner, R. J., Mar 2022, In: Journal of Neurosurgery: Spine. 36, 3, p. 464-469 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Neurolymphomatosis 100%
  • Cauda Equina 73%
  • Spinal Nerves 23%
  • Biopsy 22%
  • Lumbosacral Plexus 18%

• PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts

  Desai, S. H., Pederson, L., LaPlant, B., Mwangi, R., Maurer, M., Young, J. R., Macon, W. R., King, R. L., Wang, Y., Cerhan, J. R., Feldman, A., Inwards, D. J., Micallef, I., Johnston, P., Porrata, L. F., Ansell, S. M., Habermann, T. M., Witzig, T. E. & Nowakowski, G. S., May 2022, In: Blood cancer journal. 12, 5, 78.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Molecular Epidemiology 100%
  • Lymphoma, Large B-Cell, Diffuse 96%
  • Survival 47%
  • Lenalidomide 37%
  • Positron-Emission Tomography 26%

• Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma

  Tun, A. M., Maliske, S., Wang, Y., Inwards, D. J., Habermann, T. M., Micallef, I., Porrata, L., Paludo, J., Bisneto, J. V., Rosenthal, A., Kharfan-Dabaja, M. A., Ansell, S. M., Nowakowski, G. S., Farooq, U. & Johnston, P. B., Sep 2022, In: Transplantation and Cellular Therapy. 28, 9, p. 610-617 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lymphoma, Large B-Cell, Diffuse 100%
  • Stem Cell Transplantation 93%
  • Progression-Free Survival 80%
  • Stem Cells 65%
  • Transplants 55%

• The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial

  Perales, M. A., Kuruvilla, J., Snider, J. T., Vadgama, S., Blissett, R., El-Moustaid, F., Smith, N. J., Patel, A. R. & Johnston, P. B., Nov 2022, In: Transplantation and Cellular Therapy. 28, 11, p. 750.e1-750.e6

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • axicabtagene ciloleucel 100%
  • B-Cell Lymphoma 53%
  • Quality-Adjusted Life Years 32%
  • Costs and Cost Analysis 22%
  • Budgets 16%

• Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study

  Cull, G., Burger, J. A., Opat, S., Gottlieb, D., Verner, E., Trotman, J., Marlton, P., Munoz, J., Johnston, P., Simpson, D., Stern, J. C., Prathikanti, R., Wu, K., Novotny, W., Huang, J. & Tam, C. S., Mar 2022, In: British journal of haematology. 196, 5, p. 1209-1218 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • zanubrutinib 100%
  • B-Cell Chronic Lymphocytic Leukemia 49%
  • Neutropenia 15%
  • Safety 9%
  • Therapeutics 7%

• Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma

  Phillips, T., Chan, H., Tam, C. S., Tedeschi, A., Johnston, P., Oh, S. Y., Opat, S., Eom, H. S., Allewelt, H., Stern, J. C., Tan, Z., Novotny, W., Huang, J. & Trotman, J., Jun 14 2022, In: Blood Advances. 6, 11, p. 3472-3479 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • zanubrutinib 100%
  • Non-Hodgkin's Lymphoma 44%
  • Follicular Lymphoma 41%
  • Lymphoma 27%
  • Progression-Free Survival 12%
• 2021

  Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel

  Wudhikarn, K., Bansal, R., Khurana, A., Hathcock, M. A., Braksick, S. A., Bennani, N. N., Paludo, J., Villasboas, J. C., Wang, Y., Johnston, P. B., Ansell, S. M. & Lin, Y., Nov 1 2021, In: American journal of hematology. 96, 11, p. E427-E430

  Research output: Contribution to journal › Letter › peer-review

  Open Access